[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369989-105":59,"doc-detail-369989-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","egfr-amplification-and-pi3k-pathway-mutations-identify-a-subset-of-breast-cancers-that-synergistically-respond-to-egfr-and-pi3k-inhibition","EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition","","EGFR family signaling is frequently dysregulated in cancer through amplification or activating mutations, yet biomarkers predicting benefit from combined EGFR/PI3K targeting in breast cancer were unclear. This study identifies a patient subset with EGFR amplification together with activating PI3K-pathway alterations that shows synergistic sensitivity to dual EGFR/PI3K inhibition. EGFR-amplified tumors occur in about 1–5% of patients and associate with shorter overall survival; up to 71% carry PI3K-pathway activating mutations. Dual inhibition more strongly suppresses mTOR and AKT signaling, reduces viability, and increases apoptosis than single agents in EGFR-amplified TNBC models. Combination therapy significantly reduces tumor volume in vivo, supporting EGFR amplification plus PI3K-pathway co-mutations as driver events and predictors of response.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/egfr-amplification-and-pi3k-pathway-mutations-identify-a-subset-of-breast-cancers-that-synergistically-respond-to-egfr-and-pi3k-inhibition/369989/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/egfr-amplification-and-pi3k-pathway-mutations-identify-a-subset-of-breast-cancers-that-synergistically-respond-to-egfr-and-pi3k-inhibition/369989.png","ImageObject",300,407,{"name":92,"@type":93},"PakDamar76","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What biomarker combination predicts response to dual EGFR/PI3K inhibition in breast cancer?","Question",{"text":112,"@type":113},"The study highlights EGFR amplification together with activating PI3K-pathway mutations as a synergistic, more responsive subgroup.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How common is EGFR amplification in breast cancer according to the study?",{"text":117,"@type":113},"EGFR amplification is reported to occur in roughly 1–5% of breast cancer patients.",{"name":119,"@type":110,"acceptedAnswer":120},"What experimental evidence supports synergy from dual EGFR/PI3K inhibition?",{"text":121,"@type":113},"In EGFR-amplified models with PI3K-pathway activation, dual inhibition more strongly reduces mTOR and AKT signaling, decreases cell viability, increases apoptosis, and produces a statistically significant reduction in tumor volume in xenografts compared with control.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369989,1790864302,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Oncogene [www.nature.com/onc](www.nature.com/onc)  \nARTICLE OPEN   \nEGFR ampliﬁcation and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFRand PI3K inhibition  \nDavid J. Wisniewski1, Donna Voeller 1, Yonit A. Addissie1, Sachin Kumar Deshmukh2, Sharon Wu2, Maryam B. Lustberg3, Darawalee Wangsa4, Danny Wangsa4, Kerstin Heselmeyer-Haddad4, Yoshimi Endo Greer 1, George W. Sledge2 and Stanley Lipkowitz 1 ✉  \nThis is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025  \nEGFR family receptor tyrosine kinase signaling is commonly dysregulated in cancer by ampliﬁcation or activating mutations. Although studies have investigated dual EGFR/PI3K inhibition in breast cancer, they have not determined biomarkers which predict success. We present evidence of a patient subset with EGFR ampliﬁcation and PI3Kinase pathway mutations in breast cancer which can be synergistically targeted by dual EGFR/PI3K inhibition. This study identiﬁed that EGFR ampliﬁcation occurs in ~1–5% of breast cancer patients with shorter overall survival compared to unampliﬁed patients. Up to 71% of EGFR ampliﬁed tumors have activating mutations in the PI3K pathway. Dual EGFR/PI3K inhibition more dramatically reduced mTOR and AKT signaling in BT20 and MDAMB-468 cells which both have EGFR ampliﬁcation and PI3K pathway activating mutations, compared to control cells. Dual inhibition synergistically reduced cell viability and increased apoptosis in MDA-MB-468 and BT20 compared to control. Single agent therapy ina BT20 xenograft model reduced tumor volume, however only the combination statistically signiﬁcantly reduced tumor volume compared to control. We conclude that EGFR ampliﬁcation with co-incident PI3K pathway mutations are driver mutations in a subset of breast cancers and present a subgroup of breast cancers that are more likely to respond to dual targeted therapy.  \nOncogene (2026) 45:15–25; [https://doi.org/10.1038/s41388-025-03634-3](https://doi.org/10.1038/s41388-025-03634-3)  \nINTRODUCTION  \nThe ErbB family is comprised of four receptor tyrosine kinases, Epidermal Growth Factor Receptor (EGFR), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4) . Upon ligand binding, the receptors hetero or homodimerize allowing them to activate downstream signaling, including phosphoinositide 3-kinases (PI3Ks) or mitogen-activated protein kinases (MAPKs), resulting in increased proliferation, inhibition of apoptosis, migration, invasion, and other pro-tumor signaling [1–4] . Mutation or overexpression of these family members are common drivers of various cancer types [5] . For example, HER2 ampliﬁcation is a driver in 12–20% of breast cancers, correlates with poor survival, and has been effectively targeted to improve outcomes in patients with HER2 ampliﬁed breast cancer [6–9] .  \nEGFR can be aberrantly activated through mutations orampliﬁcation/overexpression, which drives pro-tumor effects in cancers such as non-small cell lung cancer, pancreatic cancer and head and neck cancer, leading to approval of EGFR targeted therapies including tyrosine kinase inhibitors (TKI’s) geﬁtinib, erlotinib, afatinib, dacomitinib, osimertinib, and vandetanib, and the monoclonal antibodies cetuximab, panitumumab and necitumumab [1, 2, 10–13] . EGFR is often expressed in basal triple negative breast cancer (TNBC), and is associated with tumor size, poor differentiation, worse relapse-free and overall survival, and  \nshorter metastasis free survival [14, 15] . Depending on the study, EGFR gene ampliﬁcation has been observed in 0.8–14% of breast cancer patients [16–19] . Mutation of EGFR in breast cancer can range from ~2 to 11% [20] . Relatively small studies looking speciﬁcally at metaplastic breast carcinomas have observedampliﬁcation of EGFR in 33–37% of patients [21, 22] . Despite these data, clinical trials investigating EGFR inhibitors have not shown great promise in breast cancer, with studie","cbCaiaXHmkUb6Dve","https://ap.wps.com/l/cbCaiaXHmkUb6Dve","pdf",2063111,11,"English","# Introduction\n# Methods\n## Materials","[{\"question\":\"What biomarker combination predicts response to dual EGFR/PI3K inhibition in breast cancer?\",\"answer\":\"The study highlights EGFR amplification together with activating PI3K-pathway mutations as a synergistic, more responsive subgroup.\"},{\"question\":\"How common is EGFR amplification in breast cancer according to the study?\",\"answer\":\"EGFR amplification is reported to occur in roughly 1–5% of breast cancer patients.\"},{\"question\":\"What experimental evidence supports synergy from dual EGFR/PI3K inhibition?\",\"answer\":\"In EGFR-amplified models with PI3K-pathway activation, dual inhibition more strongly reduces mTOR and AKT signaling, decreases cell viability, increases apoptosis, and produces a statistically significant reduction in tumor volume in xenografts compared with control.\"}]","EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition | PDF",1790186179,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aae3750bc32b95709ef00104aab94355.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfc7f298f0a43c2253c905c8ee766efc.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ffd71f67e141306c136dfd617f52026.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73dab8b3590096d9a85195c01553e9f0.webp",980,1301]